Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab and Umbralisib with Venetoclax or Lenalidomide in R/R CLL/NHL
NCT03379051Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab, umbralisib in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by TG Therapeutics, Inc.. Started Mar 2018; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03379051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379051.